Bioventus Inc. (NASDAQ:BVS) Stock Has Average Price Target of $16.80

Bioventus Inc. (NASDAQ:BVS) has been given an average rating of “Moderate Buy” by the six ratings firms that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average twelve-month target price among brokers that have issued a report on the stock in the last year is $16.80.

BVS has been the topic of a number of recent analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $15.00 price target on shares of Bioventus in a research note on Monday, August 17th. Craig Hallum restated a “buy” rating and set a $18.00 target price on shares of Bioventus in a research report on Thursday, August 6th. Barrington Research set a $18.00 target price on shares of Bioventus in a report on Thursday, August 6th. Canaccord Genuity Group boosted their price target on Bioventus from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Monday, August 17th. Finally, Weiss Ratings raised Bioventus from a “hold (c)” rating to a “hold (c+)” rating in a research note on Thursday, August 6th.

Bioventus Trading Down 2.6%

NASDAQ BVS opened at $13.63 on Monday. The company has a quick ratio of 1.17, a current ratio of 1.69 and a debt-to-equity ratio of 0.83. The stock has a market capitalization of $1.15 billion, a P/E ratio of 17.70, a P/E/G ratio of 1.78 and a beta of 0.65. Bioventus has a 52-week low of $6.37 and a 52-week high of $15.89. The firm has a 50-day moving average price of $13.64 and a 200 day moving average price of $11.15.

Bioventus (NASDAQ:BVS) last released its earnings results on Wednesday, August 5th. The company reported $0.22 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.22. The company had revenue of $153.21 million for the quarter. Bioventus had a return on equity of 28.08% and a net margin of 9.36%.Bioventus has set its FY 2026 guidance at 0.750-0.790 EPS. Equities research analysts expect that Bioventus will post 0.79 EPS for the current year.

Institutional Investors Weigh In On Bioventus

Several institutional investors and hedge funds have recently made changes to their positions in the business. Squarepoint Ops LLC lifted its stake in Bioventus by 21.9% in the 2nd quarter. Squarepoint Ops LLC now owns 269,267 shares of the company’s stock valued at $2,542,000 after buying an additional 48,414 shares in the last quarter. Globeflex Capital L P purchased a new position in Bioventus during the second quarter worth $1,566,000. Bank of New York Mellon Corp acquired a new position in shares of Bioventus in the second quarter worth $1,438,000. Bank of America Corp DE raised its holdings in shares of Bioventus by 40.3% in the first quarter. Bank of America Corp DE now owns 86,057 shares of the company’s stock worth $786,000 after acquiring an additional 24,723 shares during the last quarter. Finally, Engine Capital Management LP purchased a new stake in shares of Bioventus in the first quarter valued at $2,876,000. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

About Bioventus

Bioventus Inc (NASDAQ:BVS) is a medical device and biologics company focused on products that support healing and improve function for patients with musculoskeletal conditions. Its portfolio is designed for use in orthopedics, sports medicine, rehabilitation and related specialties.

The company’s products include bone-healing systems, such as EXOGEN, which uses ultrasound technology to support fracture healing, as well as osteoarthritis treatments including injectable hyaluronic acid products such as DUROLANE and GELSYN-3.